4 citations · 5 across the 9 of their papers we have counts for
8 papers · 1 filter
A Bayesian time-to-event pharmacokinetic model for sequential phase I dose-escalation trials with multiple schedules
Burak Kürsad Günhan, Sebastian Weber, Abdelkader Seroutou +1
Phase I dose-escalation trials constitute the first step in investigating the safety of potentially promising drugs in humans. Conventional methods for phase I dose-escalation tria…
Recent advances in methodology for clinical trials in small populations: the InSPiRe project
T. Friede, M. Posch, S. Zohar +19
Where there are a limited number of patients, such as in a rare disease, clinical trials in these small populations present several challenges, including statistical issues. This l…
Contribution to the discussion of "When should meta-analysis avoid making hidden normality assumptions?": A Bayesian perspective
Christian Röver, Tim Friede
Contribution to the discussion of "When should meta-analysis avoid making hidden normality assumptions?" by Dan Jackson and Ian R. White (2018; https://doi.org/10.1002/bimj.2018000…
Meta-analysis of few studies involving rare events
Burak Kürsad Günhan, Christian Röver, Tim Friede
Meta-analyses of clinical trials targeting rare events face particular challenges when the data lack adequate numbers of events for all treatment arms. Especially when the number o…
Likelihood-based meta-analysis with few studies: Empirical and simulation studies
Svenja E. Seide, Christian Röver, Tim Friede
Standard random-effects meta-analysis methods perform poorly when applied to few studies only. Such settings however are commonly encountered in practice. It is unclear, whether or…
Dynamically borrowing strength from another study through shrinkage estimation
Christian Röver, Tim Friede
Meta-analytic methods may be used to combine evidence from different sources of information. Quite commonly, the normal-normal hierarchical model (NNHM) including a random-effect t…